Every patient's cancer cells are unique to that patient and unique to every other patient's cancer cells, even patients with an identical cancer classification (e.g. breast, lung, etc.). Which is why a favorable treatment response from one patient may very well be unfavorable response to another patient.

Yet, most U.S. cancer centers completely disregard the critical importance of discerning this cellular uniqueness, administering a “one size fits all” medicine that completely disregards the critical nature of that patient's unique cancer cells, thus, very possibly administering a treating medicine that does not illicit cellular death to that patient's unique cancer cells.

ICCA physicians are fully aware of these shortcomings, and confident that ICCA patients can see upwards of a 100% greater treatment efficacy over conventional cancer treatments when the CoNexus Cancer Cancer treatment includes in-vitro functional tumor cell profiling - a laboratory technique that measures how that patient's unique cancer cells will respond when exposed to medicines shown to illicit cellular death in the laboratory.

Our tumor cell profiled targeting agents are so gentle, many patients report having no debilitating side-effects whatsoever. Clearly this is a powerful tool to fight late stage cancers but represents only a portion of our CoNexus Cancer Care treatment approach.

ICCA physicians have employed unique treatment options to late-stage and complex cancers for over forty years, and especially skilled at treating persistently resistant cancers. Many patients who have struggled with a resistant or complex form of cancer have experienced significant benefits from undergoing CoNexus Cancer Care therapies.

By incorporating four decades of clinical experience with advanced tumor cell profiling and other proprietary treatments, Integrative Cancer Centers is better able to treat any cancer at a specifically customized level. Our cancer treatment is based upon sound research, development, and clinical application, always at the forefront of globally driven innovation.

It is our tumor board's opinion, that a comprehensive treatment protocol composed of functional tumor cell profiling, tumor targeted immunotherapy, and an autologous dendritic cell vaccine is ideal for achieving lasting long-term results when fighting aggressive late stage cancers.

Effective outcomes mean treating cancer from multiple angles via continuing research, updated treatment protocols, targets, and delivery techniques. One innovation is our tumor-targeted immunotherapy which injected directly into the tumor under CT image guidance. Tumor targeting allows image guided, functional tumor cell profiled chemotherapy, integrative agents, and immunotherapy agents to be placed directly into the tumor. This minimally invasive procedure provides targeting agents with 100% delivery to the tumors while also initiating a systemic immune response which is why our interventional radiology team has become such an important part of our vast array of advanced cancer treatment technologies.

For over thirty years, ICCA physicians have focused on treating all late state primary and metastatic tumors, including breast, pancreas, liver, lung, colon/stomach, prostate, head, and neck; amongst many other solid or blood types.

Integrative Cancer Centers of America does not make any guarantee of outcomes. Results are not typical and will vary from person to person and should not be expected.